Shu-na Yao

27 Dongming Road
Zhengzhou, 450008, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 10 publications

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review.

Low incidence of hepatitis B virus reactivation in patients with hematological malignancies receiving novel anticancer drugs: A report from a high epidemic area and literature review.

Journal: Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi

Published: November 25, 2022

Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.

Camrelizumab plus apatinib successfully treated a patient with advanced esophageal squamous cell carcinoma.

Journal: Immunotherapy

Published: August 21, 2020

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.

Combining PD-1 Inhibitor Nivolumab with Radiotherapy Successfully Treated a Patient with Refractory Primary Mediastinal Large B-Cell Lymphoma: A Case Report and Literature Review.

Journal: Cancer management and research

Published: March 15, 2020

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.

Safety and Efficacy of Chemotherapy Combined with Anlotinib Plus Anlotinib Maintenance in Chinese Patients with Advanced/Metastatic Soft Tissue Sarcoma.

Journal: OncoTargets and therapy

Published: October 20, 2019

L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.

L-Type Cav 1.2 Calcium Channel-α-1C Regulates Response to Rituximab in Diffuse Large B-Cell Lymphoma.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: July 06, 2018

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.

Weekly nanoparticle albumin-bound paclitaxel in combination with cisplatin versus weekly solvent-based paclitaxel plus cisplatin as first-line therapy in Chinese patients with advanced esophageal squamous cell carcinoma.

Journal: OncoTargets and therapy

Published: October 08, 2016

A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.

A retrospective clinical study of comparing paclitaxel plus S-1 versus paclitaxel plus cisplatin as the first-line treatment for patients with advanced esophageal squamous cell carcinoma.

Journal: Oncotarget

Published: July 18, 2016

Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.

Efficacy of gemcitabine combined with oxaliplatin, L-asparaginase and dexamethasone in patients with newly-diagnosed extranodal NK/T-cell lymphoma.

Journal: Molecular and clinical oncology

Published: May 23, 2014

Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism

Inhibitory effects of celecoxib combined with capecitabine on H22 hepatoma mice and its mechanism

Journal: Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Published: August 31, 2013

p63 Expression is a prognostic factor in colorectal cancer.

p63 Expression is a prognostic factor in colorectal cancer.

Journal: The International journal of biological markers

Published: August 01, 2012

Showing 1-10 of 10

Last Updated: 09/26/2026